FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Zeronda Tyler		 2. Date of Event Requiring Statement (MM/DD/YYYY)
6/18/2021 

 3. Issuer Name and Ticker or Trading Symbol

VYNE Therapeutics Inc. [VYNE]
(Last)        (First)        (Middle)

C/O VYNE THERAPEUTICS, INC., 520 U.S. HIGHWAY 22, SUITE 204		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Interim CFO /
(Street)

BRIDGEWATER, NJ 08807      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 23395 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option  (2)5/16/2029 Common Stock 13504 $5.92 D  
Stock Option  (3)3/19/2030 Common Stock 4375 $10.68 D  
Stock Option  (4)5/6/2030 Common Stock 9375 $7.80 D  
Stock Option  (5)3/4/2031 Common Stock 18834 $6.68 D  
Explanation of Responses:
(1) This amount includes 18,853 shares underlying unvested restricted stock units that will vest over four years following the date of grant.
(2) The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option vested on June 30, 2020 and 6.25% of the shares vest on the last day of each quarter thereafter.
(3) The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option vested on March 31, 2021 and 6.25% of the shares will vest on the last day of each quarter thereafter.
(4) The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on June 30, 2021 and 6.25% of the shares will vest on the last day of each quarter thereafter.
(5) The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2022 and 6.25% of the shares will vest on the last day of each quarter thereafter.

Remarks:
The reporting person was not granted any additional awards in connection with his appointment as interim CFO of the Issuer.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Zeronda Tyler
C/O VYNE THERAPEUTICS, INC.
520 U.S. HIGHWAY 22, SUITE 204
BRIDGEWATER, NJ 08807

Interim CFO
Signatures
/s/ Mutya Harsch, attorney-in-fact for Tyler Zeronda6/21/2021
**Signature of Reporting PersonDate
Menlo Therapeutics (NASDAQ:MNLO)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Menlo Therapeutics.
Menlo Therapeutics (NASDAQ:MNLO)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Menlo Therapeutics.